Navigation Links
MicroPhage Closes Latest Financing
Date:11/20/2008

LONGMONT, Colo., Nov. 20 /PRNewswire/ -- MicroPhage, Inc., http://www.microphage.com, today announced it has concluded its latest round of financing, which brings total capital raised to $11 million. Investors in this round were a combination of existing and new investors. All funds to date have come from private investors.

MicroPhage will apply proceeds of its financing to complete the validation and launch preparation of their initial diagnostic products, which address the growing need for simple, rapid and highly accurate tests for hospital-acquired infections (HAIs), such as MRSA.

R. Gary Mesch, chairman of MicroPhage commented "MicroPhage investors are confident the company will deliver badly needed diagnostic tools in the fight against MRSA and other HAIs. Closing a significant funding round in this tough financial climate is a noteworthy achievement."

MicroPhage CEO Steve Lundy added: "We have been validating our products in the field and have received excellent feedback from laboratory professionals who tested them against current methods. We are looking forward to completing our validation work and launching products, which leverage the tremendous power of bacteriophage amplification technology for rapid bacterial identification and susceptibility testing."

About MicroPhage

Based in Longmont, Colo. and privately held, MicroPhage, Inc. is working to be a global leader in developing rapid diagnostics products for bacterial identification and antibiotic susceptibility/resistance testing. Using its bacteriophage-based amplification platform, the company has developed a patented process that is a product platform or engine for rapid, easy-to-use, inexpensive diagnostic tests. Its first products, expected in late 2009, will set a new standard for clinicians in MRSA identification and antibiotic susceptibility testi
'/>"/>

SOURCE MicroPhage, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
2. CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
3. Starfish Ventures Closes Australias Largest Venture Capital Fund With $185 Million Tech Fund
4. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
5. Great Basin Scientific, Inc. Closes $3.9 Million in Equity Funding
6. Micromet Closes $40 Million Private Equity Placement
7. Helix Biopharma Closes $11.4 Million Private Placement
8. ForteBio, Inc. Closes $25 Million In Series C Financing
9. AMDL, Inc. Closes Private Placement of Convertible Notes
10. World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round
11. Pathwork Diagnostics Closes $20M Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... -- BioMed Realty Trust, Inc. (NYSE: BMR ) announ...s from lenders to increase the borrowing capacity ...an aggregate of $665 million, with no other change...age effective interest rate of the unsecured line ...maturity date remains August 1, 2011, which may be...
(Date:11/9/2009)...harmaceutical giants use Datafarm for production o...rm’s announcement comes on the heels of last...e Health Canada stated that, effective immediately...ory submissions for New Drug Submission (NDS) appl... Marlborough, MA (PRWEB) Novemb...
(Date:11/7/2009)...- Research projects in the areas of mathematics an...im Kunisky of Livingston, NJ and the team of Benja...ved the highest honors at the Region Five Finals o...mp; Technology, the nation,s premier high school s...m/cgi-bin/prnh/20070904/SIEMENSLOGO ) ,, Toni...
(Date:11/6/2009)...ire/ -- EUCODIS Bioscience, a company,developing, ...for the,chemical industry announced today that it ...us, the leading biopharmaceutical company in Latin...ioscience exclusive access - for the search,of enz...ction of,psychrophilic bacteria strains and other ...
Breaking Biology Technology:BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 2BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 3Datafarm Responds to Health Canada's Announcement of Hybrid eCTD Submission Procedural Simplification 2Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 2Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 3Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 4Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 5Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 6EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2
...MISSISSAUGA, ON, Dec. 20 /PRNewswire-FirstCall/ - ...BA), an oncology company that identifies,develops ...ients worldwide,today announced that it has comple...Phase II trial of nimotuzumab in combination with ... The safety profile in the trial to,date is consis...
...Avon Walk Adds Houston, TX to 2008 Lineup; Looks t...eaking Results, NEW YORK, Dec. 20 Underscoring i...e and finding a cure for breast cancer, the Avon,F...reast Cancer schedule.,For the first time in Avon ...market -- Houston -- to build upon the momentum of...
...CARLSBAD, Calif., Dec. 20 Ardea Biosciences,Inc. ...ry and development of,small-molecule therapeutics ...flammatory diseases, today announced that it has e...ertain institutional investors to raise,approximat...oximately 3.0,million newly issued shares of its c...
Other Biology Technology:YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 3Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 2Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 3Ardea Biosciences Announces $40 Million Private Placement 2Ardea Biosciences Announces $40 Million Private Placement 3
(Date:11/9/2009)...RMINGHAM, Ala. The U.S. Department of Energy (DOE...ersity of Alabama at Birmingham (UAB) School of En...reenhouse gas emissions through the capture and pe...dioxide (CO2). The project is in collaboration wit...Power. , Funded by the DOE through the 2009 Amer...
(Date:11/9/2009)...am of academic, government and industry researcher...hot esculenta) genome. The project is an important...n this subsistence crop and addressing some of the... the world. , Cassava is a root crop that serves...ion people each day. Although it has many properti...
(Date:11/9/2009)..., the Netherlands, November 09, 2009 / b3c newswi...anization, and Seventh Wave, an American organizat...e that the companies have signed a letter of inten...estinal models TIM. The letter of intent proposes ...two TIM systems for commercialization in North Ame...
Breaking Biology News(10 mins):UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2LeadConfirm Professional the First Oral Based Lead Test Makes Getting the Lead Out Easier Now Available at Amazon com 51078 1LeadConfirm Professional the First Oral Based Lead Test Makes Getting the Lead Out Easier Now Available at Amazon com 51078 2LeadConfirm Professional the First Oral Based Lead Test Makes Getting the Lead Out Easier Now Available at Amazon com 51078 3LeadConfirm Professional the First Oral Based Lead Test Makes Getting the Lead Out Easier Now Available at Amazon com 51078 4Team Golds Gym Continues to Lead the National Fight Against Diabetes 51073 1Team Golds Gym Continues to Lead the National Fight Against Diabetes 51073 2Team Golds Gym Continues to Lead the National Fight Against Diabetes 51073 3VirtualScopics Reports Record Revenue 51069 1VirtualScopics Reports Record Revenue 51069 2
..., MADISON Individuals with a rare genetic conditi...ficult-to-follow prescription. They must severely ...iding mealtime staples such as meat, cheese and ev...nstant struggle. , In an effort to expand their di...adison scientists is assessing a unique protein fo...
...ASHINGTON, Feb. 1 The U.S. Department of Homeland...collecting additional,fingerprints from internatio...continental Airport (Bush Intercontinental). The c...- to 10-fingerprint collection to enhance,security...ly and,efficiently establishing and verifying visi...
... The Stowers Institutes Trainor Lab has demonstra...development of the nervous system, a process that ...re neural cells with the cycle of cell division th...sms regulating these distinct cellular activities ...l be published in the Feb. 15 issue of Development...
Other Biology News:Unique whey protein is promising supplement for strict PKU diet 2Unique whey protein is promising supplement for strict PKU diet 3DHS Begins Collecting 10 Fingerprints From International Visitors at George Bush Houston Intercontinental Airport 2Trainor Lab characterizes gene essential for prenatal development of nervous system 2
Anti-MPM-2, phospho-Ser / Thr-Pro (Mitotic protein monoclonal #2) Antibody, Agarose Conjugated from Upstate
Goat Anti-TNFalpha-IP 2 (G-17) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Mouse Anti-Neuropilin-2 Monoclonal Antibody, Unconjugated, Clone 54 from BD Biosciences Pharmingen
cAMP Competitive immunoassay Assay Kit, HTRF from Cisbio
Biology Products: